BioPharmSignal logoBioPharmSignal

Biotech News

ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update

ALX Oncology (ALXO)ALX OncologyEarnings

- Data from Phase 1b/2 trial of evorpacept + zanidatamab presented at ESMO Breast Cancer 2026 showed all patients with confirmed HER2-positive disease and high CD47 expression experienced durable responses to this combination - - Evorpacept data from two independent HER2-positive trials strengthens

Related news

ALXOALX Oncology2026-08-06 12:00 EST

ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update

RLAYRelay Therapeutics2026-08-06 20:05 EST

Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates

CMPXCompass Therapeutics2026-08-06 11:30 EST

Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update

CGEMCullinan Therapeutics, Inc.2026-08-06 11:00 EST

Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

CHRSCoherus BioSciences, Inc.2026-08-05 20:28 EST

Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update

BMEABiomea Fusion2026-08-05 20:05 EST

Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights

EXELExelixis2026-08-05 20:05 EST

Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update

RVMDRevolution Medicines2026-08-05 20:02 EST

Revolution Medicines Reports Second Quarter 2026 Financial Results and Update on Corporate Progress

BNTXBioNTech2026-08-04 10:45 EST

BioNTech Announces Second Quarter 2026 Financial Results and Corporate Update

RLAYRelay Therapeutics2026-07-30 20:05 EST

Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026

View all latest news

ALX Oncology

CD47-Directed Immuno-Oncology ALX Oncology develops therapies intended to activate innate and adaptive antitumor immunity. Its lead approach blocks CD47 signaling while seeking to avoid broad binding to healthy cells. Evorpacept Evorpacept is a high-affinity CD47 blocker designed for combination with tumor-targeting antibodies and other...

Recent company news

ALXOALX Oncology2026-08-06 12:00 EST

ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update

ALXOALX Oncology2026-06-30 20:40 EST

ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules

ALXOALX Oncology2026-06-30 12:00 EST

ALX Oncology Appoints Scott Garland as Chairman of the Board and Michael Listgarten as General Counsel

ALXOALX Oncology2026-06-01 12:00 EST

ALX Oncology to Present at the 2026 Jefferies Global Healthcare Conference in New York

ALXOALX Oncology2026-05-08 12:00 EST

ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update

Stock data

Close
2.11 USD
Market cap
239.52M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States